Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02241785 · ClinicalTrials.gov registry record · Phase 4
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
A Phase 4 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 4
- Development phase
- 47
- Enrollment target
NCT02241785 is a Phase 4 study that was terminated before completion, run by Biogen. The registered enrollment target is 47 participants.
The verdict
NCT02241785, a Phase 4 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 47 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the efficacy of natalizumab (Tysabri, BG00002) in participants with relapsing forms of multiple sclerosis (MS) who have failed Gilenya or BRACET (Betaseron, Rebif, Avonex, Copaxone, Extavia, Tecfidera) as measured by the proportion of participants with no evidence of disease activity (NEDA) at Year 1. The secondary objectives in this study population are: change in total T1 hypointense and total T2 hyperintense lesion volume; proportion of participants with NEDA at Year 2; evaluation of the impact of natalizumab on annualized relapse rate (ARR); and change in Multiple Sclerosis Impact Scale-29 (MSIS-29) physical impact score.
Interventions
- DRUG natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2014-09-30 |
| Est. Completion | 2016-05-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02241785
The ClinicalTrials.gov registry entry for NCT02241785 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which natalizumab is the first listed.
NCT02241785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02241785 about?
NCT02241785 is a clinical study titled "Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies". The primary objective of the study is to determine the efficacy of natalizumab (Tysabri, BG00002) in participants with relapsing forms of multiple sclerosis (MS) who have failed Gilenya or BRACET (Betaseron, Rebif, Avonex, Copaxone, Extavia, Tecfidera) as measured by the proportion of participants w...
What is the current status of trial NCT02241785?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 47 participants. The study started on 2014-09-30. Estimated completion is 2016-05-02.
What interventions are being tested in trial NCT02241785?
The interventions under investigation include: natalizumab (DRUG).
Who is sponsoring clinical trial NCT02241785?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.